Misonix, Inc. (Nasdaq: MSON) today announced major milestones for the Sonablate(R) 500 (“SB500"), a medical device using high intensity focused ultrasound (“HIFU”) for non-invasive treatment of prostate cancer, at the American Urological Association’s Annual Conference, held from May 19-24 in Anaheim, CA. Medical experts in the field of urology from around the world attended the conference and celebrated the milestones achieved by the SB500 which has now been used in 6,000 treatments in over 100 clinics over the past six years.
